Logo

ATXS

Astria Therapeutics, Inc.

ATXS

Astria Therapeutics, Inc. • NASDAQ
$12.65 ▲ 0.40% (+0.05)
Market Cap $722.12 M
52w High $12.71
52w Low $3.56
Dividend Yield 0%
P/E -5.91
Volume 244.04K
Outstanding Shares 57.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $706K ▲ $34.81M ▼ $-31.643M ▲ -4.482K% ▼ $-0.55 ▲ $-31.643M ▲
Q2-2025 $0 $35.82M ▼ $-33.052M ▲ 0% $-0.57 ▲ $-35.82M ▲
Q1-2025 $0 $36.995M ▲ $-33.709M ▼ 0% $-0.58 ▼ $-36.995M ▼
Q4-2024 $0 $29.591M ▲ $-25.626M ▼ 0% $-0.45 ▼ $-29.591M ▼
Q3-2024 $0 $29.014M $-24.534M 0% $-0.43 $-29.014M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $227.721M ▼ $271.866M ▼ $38.613M ▲ $233.253M ▼
Q2-2025 $259.178M ▼ $281.924M ▼ $21.412M ▲ $260.512M ▼
Q1-2025 $295.064M ▼ $310.387M ▼ $21.097M ▼ $289.29M ▼
Q4-2024 $328.132M ▼ $342.363M ▼ $23.1M ▲ $319.263M ▼
Q3-2024 $344.283M $361.639M $19.985M $341.654M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-31.643M ▲ $-32.295M ▲ $52.253M ▼ $3K ▲ $19.961M ▼ $-32.295M ▲
Q2-2025 $-33.052M ▲ $-36.058M ▼ $57.992M ▲ $0 $21.934M ▲ $-36.648M ▼
Q1-2025 $-33.709M ▼ $-34.018M ▼ $28.583M ▲ $0 $-5.435M ▲ $-34.018M ▼
Q4-2024 $-25.626M ▼ $-17.362M ▲ $-3.717M ▼ $0 ▼ $-21.079M ▼ $-17.362M ▲
Q3-2024 $-24.534M $-27.965M $6.188M $15.301M $-6.476M $-27.985M

Five-Year Company Overview

Income Statement

Income Statement Astria is still a pure R&D-stage biotech, so it has no product revenue yet and relies entirely on external funding. The company has posted steady operating and net losses over the past several years, which is typical for a business that is investing heavily in drug development before commercialization. Losses have generally grown and then stabilized as clinical programs advanced, reflecting higher research and development and corporate costs. Earnings per share look volatile largely because of past reverse stock splits rather than big shifts in the underlying business. Overall, the income statement shows a company firmly in the investment phase, not yet in the earnings phase.

Balance Sheet

Balance Sheet The balance sheet shows a relatively simple and conservative structure. Astria holds a meaningful cash balance relative to its size, and total assets have increased over time as the company raised capital to fund trials. Shareholders’ equity has also grown, indicating that the company has mainly financed itself through issuing stock rather than taking on debt. Borrowings are minimal, so financial leverage is low. The main risk is not over-indebtedness but the future need to replenish cash as it continues to spend on clinical development without revenue coming in.

Cash Flow

Cash Flow Astria consistently uses cash in its operations, reflecting ongoing research, clinical trials, and overhead, with no offsetting product sales yet. Cash outflows from operations have been steady rather than exploding, suggesting a controlled but persistent cash burn. Capital spending on physical assets is negligible; almost all cash use is for R&D and running the business. Free cash flow is therefore negative and closely tracks operating cash flow. The company’s ability to continue funding its programs depends on periodic access to capital markets or partnerships as current cash is drawn down over time.

Competitive Edge

Competitive Edge Astria operates in a specialist corner of biotechnology focused on allergic and immunologic diseases, particularly hereditary angioedema and atopic dermatitis. In hereditary angioedema, the lead candidate is designed to be dosed far less frequently than many existing preventive treatments, which could be a strong differentiator if safety and efficacy hold up. In atopic dermatitis, the company is targeting an established but competitive field, where new entrants need clear advantages in effectiveness, side effects, or convenience. Astria faces competition from much larger pharmaceutical companies with deeper resources, but its narrow focus and potential dosing-convenience edge give it a defined niche. Its competitive strength will ultimately depend on late-stage clinical results, regulatory outcomes, and how rival therapies evolve over the next few years.

Innovation and R&D

Innovation and R&D Innovation is the core of Astria’s value. The company is building long-acting antibody therapies aimed at turning frequent injections into infrequent, maintenance-style treatments. The lead hereditary angioedema program has already shown encouraging early clinical results with extended dosing intervals, signaling a meaningful quality-of-life improvement if confirmed in larger trials. The atopic dermatitis program targets a known immune pathway with the goal of delivering strong and durable control of inflammation with fewer doses. Astria’s R&D strategy is focused and relatively concentrated in just a couple of programs, which increases both the potential upside if they succeed and the risk if any major trial or safety setback occurs. Continuous data readouts, regulatory interactions, and any expansion of the pipeline will be key markers of how its innovation story is progressing.

Summary

Astria Therapeutics is a classic early-stage biotech: no revenue yet, ongoing losses, and a balance sheet supported primarily by equity capital. Its financial profile reflects a company spending steadily on research and clinical trials while keeping debt low. The main financial risk is the need for future funding to support continued development, given persistent cash burn. Strategically, the company is tightly focused on long-acting antibody therapies for allergic and immunologic diseases, with hereditary angioedema and atopic dermatitis at the forefront. Its potential competitive edge lies in making treatments far less burdensome through infrequent dosing, backed by promising early clinical data. However, success depends on navigating clinical, regulatory, and competitive hurdles in areas where larger players are also active. Overall, Astria’s story is about trading near-term financial losses for the possibility of future high-impact therapies, with outcomes hinging on a small number of key drug candidates and trial milestones.

NEWS

November 12, 2025 · 8:00 AM UTC

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Read more

November 6, 2025 · 8:00 AM UTC

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Read more

October 31, 2025 · 8:00 AM UTC

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Read more

October 17, 2025 · 3:20 PM UTC

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Read more

October 15, 2025 · 7:30 AM UTC

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders

Read more